Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dubsky, P; Filipits, M; Jakesz, R; Rudas, M; Singer, CF; Greil, R; Dietze, O; Luisser, I; Klug, E; Sedivy, R; Bachner, M; Mayr, D; Schmidt, M; Gehrmann, MC; Petry, C; Weber, KE; Kronenwett, R; Brase, JC; Gnant, M; Austrian Breast and Colorectal Cancer Study Group (ABCSG)..
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Ann Oncol. 2013; 24(3):640-647
Doi: 10.1093/annonc/mds334
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Hofmann Guenter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed. Patients and methods: We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPclin. Prognostic groups were compared using the Kaplan-Meier survival analysis. Results: After 10 years, absolute risk reductions (ARR) between the high- and low-risk groups ranged from 6.9% to 11.2% if assigned according to guidelines. It was at 18.7% for EPclin. EPclin reassigned 58%-61% of women classified as high-/intermediate-risk (according to clinical guidelines) to low risk. Women reclassified to low risk showed a 5% rate of distant metastasis at 10 years. Conclusion: The EPclin score is able to predict favorable prognosis in a majority of patients that clinical guidelines would assign to intermediate or high risk. EPclin may reduce the indications for chemotherapy in ER-positive postmenopausal women with a limited number of clinical risk factors.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents, Hormonal - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - classification Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - mortality
- Chemotherapy, Adjuvant -
- Disease-Free Survival -
- Female -
- Humans -
- Kaplan-Meier Estimate -
- Middle Aged -
- Nitriles - administration & dosage
- Practice Guidelines as Topic -
- Prognosis -
- Receptor, erbB-2 - metabolism
- Receptors, Estrogen - metabolism
- Retrospective Studies -
- Risk Assessment -
- Tamoxifen - administration & dosage
- Treatment Outcome -
- Triazoles - administration & dosage
- Find related publications in this database (Keywords)
- adjuvant treatment
- breast cancer
- endocrine therapy
- EndoPredict gene
- expression